Ting Zhou

AUG 10, 2026 · JOURNAL ARTICLE

Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations

JAMA

Phase 3 RCT with adequately powered, pre-specified primary endpoint showing clinically significant and statistically robust PFS benefit (HR 0.44, p<.001) in a well-defined population, though OS remains immature and generalizability is limited to China.

AUG 10, 2026 · PREPRINT

Beyond Solvability: Task Learnability as a Static Prior for LLM RL Post-Training

arXiv

Early-stage empirical work proposing a new method for task selection in LLM post-training, demonstrated on benchmarks but without peer review, hard endpoints, or evidence of deployment impact.